Search Results - "Shaw, H.M."

Afatinib use in non-small cell lung cancer previously sensitive to epidermal growth factor receptor inhibitors: The United Kingdom Named Patient Programme by Khan, F, Ottensmeier, C, Popat, S, Dua, D, Dorey, N, Ellis, S, Szabo, M, Upadhyay, S, Califano, R, Chan, S, Lee, L, Ali, C.W, Nicolson, M, Bates, A.T, Button, M, Chaudhuri, A, Mulvenna, P, Shaw, H.M, Danson, S.J

“…Abstract Introduction Afatinib prolongs progression-free survival (PFS) in patients with non-small cell lung cancer (NSCLC) who were previously sensitive to…”
Get full text

Detection of second primary cutaneous melanomas by Francken, A.B, Shaw, H.M, Thompson, J.F

“…Abstract Aims There have been few studies investigating the value of follow-up in the detection of second primary melanomas (SPMs) and there is scant…”
Get full text

1704P COVID-19 mortality in patients receiving anti-cancer therapy in a UK national cancer centre by Wu, A., Sng, C.C.T., Benafif, S., Chopra, N., Galazi, M., Lee, A.J.X., Ottaviani, D., Soosaipillai, G.B., Wong, Y.N.S., Shaw, H.M.

Get full text

1734P Do cancer patients really do worse? A study in a UK tertiary hospital within a COVID-19 epicentre by Sng, C.C.T., Wu, A., Wong, Y.N.S., Soosaipillai, G.B., Ottaviani, D., Lee, A.J.X., Galazi, M., Chopra, N., Benafif, S., Shaw, H.M.

Get full text

LBA73 - SELPAC: A 3 arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel (PT) in metastatic uveal melanoma (UM) by Nathan, P., Needham, A., Corrie, P.G., Danson, S., Evans, J., Ochsenreither, S., Kumar, S., Goodman, A., Larkin, J.M.G., Karydis, I., Steven, N.M., Lorigan, P., Plummer, R., Patel, P., Shaw, H.M., Leyvraz, S., Rawcliffe, C., Psarelli, E.E., Handley, L., Sacco, J.J.

“…The MAPK pathway is constitutively activated in uveal melanoma (UM), a disease for which there remains no standard of care for metastatic disease. In a…”
Get full text

SELPAC: A 3 arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel (PT) in metastatic uveal melanoma (UM) by Nathan, P., Needham, A., Corrie, P.G., Danson, S., Evans, J., Ochsenreither, S., Kumar, S., Goodman, A., Larkin, J.M.G., Karydis, I., Steven, N.M., Lorigan, P., Plummer, R., Patel, P., Shaw, H.M., Leyvraz, S., Rawcliffe, C., Psarelli, E.E., Handley, L., Sacco, J.J.

Get full text

1373TiP - ILLUMINATE 301: A randomized phase III study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy by Butler, M.O., Robert, C., Negrier, S., In, G.K., Walker, J., Krajsova, I., Atkinson, V.G., Hansson, J., Kapiteijn, E., Loquai, C., Shaw, H.M., Cheng, T., Mansard, S., Grob, J.J., Guidoboni, M., Mehta, M., Ascierto, P.A., Diab, A.

“…Tilsotolimod (IMO-2125) is a Toll-like receptor (TLR) 9 agonist with potent immunostimulating activity. In an ongoing phase I/II clinical study in patients…”
Get full text

ILLUMINATE 301: A randomized phase III study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy by Butler, M.O., Robert, C., Negrier, S., In, G.K., Walker, J., Krajsova, I., Atkinson, V.G., Hansson, J., Kapiteijn, E., Loquai, C., Shaw, H.M., Cheng, T., Mansard, S., Grob, J.J., Guidoboni, M., Mehta, M., Ascierto, P.A., Diab, A.

Get full text

ILLUMINATE 301: A randomized phase III comparison of IMO-2125 with ipilimumab (ipi) versus ipi alone in subjects with anti PD 1 refractory melanoma by Ascierto, P.A., Arenberger, P., Atkinson, V.G., Hansson, J., Kapiteijn, E., Loquai, C., Negrier, S., Shaw, H.M., Tarhini, A., Walker, J., Geib, J., Rahimian, S., Swann, S., Diab, A.

Get full text

The use of next generation sequencing (NGS) to guide patient selection for phase 1 clinical trials by Miller, R.E., Brown, N.F., Speirs, A., Shaw, H.M., Adeleke, S., Gougis, P., Bennett, P., Meyer, T., Swanton, C., Forster, M., Kristeleit, R.S.

Get full text

49 ORAL Improvement of survival: prognostic factors in relapsed cutaneous melanoma patients by Francken, A.B., Shaw, H.M., Soong, S.J., Accortt, N.A., Thompson, J.F.

Get full text

Letter to the editor by Shaw, H.M, Scolyer, R.A, Thompson, J.F

Get full text

PII: S1479-666X(07)80037-0 by Shaw, H.M., Scolyer, R.A., Thompson, J.F.

Get full text

PII: S1479-666X(07)80038-2 by Shaw, H.M., Scolyer, R.A., Thompson, J.F.

Get full text

Letter to the editor by Shaw, H.M, Scolyer, R.A, Thompson, J.F

Get full text

Prognostic value of sentinel lymph node biopsy by Shaw, H.M., Thompson, J.F.

Get full text

Prognostic significance of a polypoid configuration in malignant melanoma by McGovern, V J, Shaw, H M, Milton, G W

“…In a review of 2296 patients with malignant melanoma, the overall incidence of a polypoid configuration was 21.5%. A markedly higher proportion of patients…”
Get more information

Who should treat patients with primary melanoma? by Thompson, J.F., Shaw, H.M.

Get full text

Regarding Pedunculated Malignant Melanoma by Shaw, H.M., Thompson, J.F.

Get full text

Regarding Amelanotic Melanomas by Shaw, H.M., Thompson, J.F.

Get full text